D. Jung

Molecular and Pharmacological Characterization of the Interaction between Human Geranylgeranyltransferase Type I and Ras-Related Protein Rap1B

H. Bachmann, Sonja Hinz, D. Jung, 2021, International journal of molecular sciences.

Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies.

T. Ellis, A. Franke, D. Jung, 2000, Hybridoma.

Analyzing the postulated inhibitory effect of Manumycin A on farnesyltransferase

H. Bachmann, L. Weber, D. Diehl, 2022, Frontiers in Chemistry.

FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer

C. Thomssen, M. Vetter, H. Bachmann, 2022, Cancers.

Enhanced Antiviral Function of Magnesium Chloride-Modified Heparin on a Broad Spectrum of Viruses

A. Baiker, A. Sing, C. Griesinger, 2021, International journal of molecular sciences.

Pharmacogenetic association of diabetes-associated genetic risk score with rapid progression of coronary artery calcification following treatment with HMG-CoA-reductase inhibitors —results of the Heinz Nixdorf Recall Study

M. Nöthen, S. Moebus, S. Pechlivanis, 2021, Naunyn-Schmiedeberg's Archives of Pharmacology.

Regulation of protein prenylation.

H. Bachmann, D. Jung, Hagen S. Bachmann, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Characterization of the promoter of the human farnesyltransferase beta subunit and the impact of the transcription factor OCT-1 on its expression.

Patrick Stelmach, I. Manthey, H. Bachmann, 2022, Genomics.

Identification of novel human adenovirus candidates using the coxsackievirus and adenovirus receptor for cell entry

A. Baiker, Wenli Zhang, A. Ehrhardt, 2020, Virology Journal.